Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study

Objective To determine whether the creatinine/cystatin C (Cr/CysC) ratio, which is influenced by muscle mass, can be used as a predictive marker of the adverse effects of chemotherapy. Methods This single-centre, retrospective, observational study assessed patients with lung cancer. Serum Cr and Cys...

Full description

Saved in:
Bibliographic Details
Published in:Journal of international medical research 2015-08, Vol.43 (4), p.573-582
Main Authors: Suzuki, Kensuke, Furuse, Hideaki, Tsuda, Takeshi, Masaki, Yasuaki, Okazawa, Seisuke, Kambara, Kenta, Inomata, Minehiko, Miwa, Toshiro, Matsui, Shoko, Kashii, Tatsuhiko, Taniguchi, Hirokazu, Hayashi, Ryuji, Tobe, Kazuyuki
Format: Article
Language:English
Subjects:
Biomarkers - blood
Carcinoma, Non-Small-Cell Lung - blood
Creatinine - blood
Cystatin C - blood
Demography
Humans
Lung Neoplasms - blood
Lung Neoplasms - drug therapy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To determine whether the creatinine/cystatin C (Cr/CysC) ratio, which is influenced by muscle mass, can be used as a predictive marker of the adverse effects of chemotherapy. Methods This single-centre, retrospective, observational study assessed patients with lung cancer. Serum Cr and CysC levels were measured once within 1 month prior the commencement of chemotherapy. Results A total of 25 patients with lung cancer were enrolled in the study: 22 received first-line therapy; three received second-line therapy. A significant difference was noted regarding the Cr/CysC ratios between patients with nonsmall-cell lung cancer (NSCLC) and those with small-cell lung cancer (0.78 versus 0.92, respectively). A significant difference was also noted in the Cr/CysC ratios of patients with NSCLC with toxicity grades
ISSN:0300-0605
1473-2300
DOI:10.1177/0300060515579116